Silence Therapeutics’ stuttering effort to generate clinical data on SLN124 in myelodysplastic syndrome (MDS) has conked out. Facing recruitment challenges, the RNAi specialist has decided to stop enrollment in the MDS arm of an early-phase clinical trial to focus on thalassemia and polycythemia vera. Source: Fierce Biotech 17/3/22